A new concept and a theoretical consideration of the mechanism-based pharmacokinetics/pharmacodynamics (PK/PD) modeling for antimicrobial agents

Japanese Journal of Antibiotics

Volumn 61, Issue 5, 2008, Pages 314-338

  Sato, Nobuo ^a   Suzuki, Hisashi ^a   Hayashi, Hiroyuki ^a   Shibasaki, Shigeki ^a   Sugano, Toshie ^a   Maebashi, Kazunori ^a   Kurosawa, Tohru ^a   Shiomi, Mari ^b   Ogata, Hiroyasu ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFDITOREN; FROPENEM; HABEKACIN; LEVOFLOXACIN; TEBIPENEM; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION (PARAMETERS); CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; PATHOGENESIS; PHARMACODYNAMICS;

ANTI-BACTERIAL AGENTS; BACTERIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; MODELS, THEORETICAL; TIME FACTORS;

EID: 57849118044     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. TENOVER, F. C.: Mechanisms of antimicrobial resistance in bacteria. Am. J. Med. 119 (6A): S3-S10, 2006
2. WRIGHT, G. D.: Bacterial resistance to antibiotics: Enzymatic degradation and modification. Adv. Drug Deliv. Rev. 57: 1451-1470, 2005
3. CRAIG, W. A.: Re-evaluating current antibiotic therapy. Respir. Med. 95 (Suppl. A): S12-S19, 2001
4. MACGOWAN, A. & K. BOWKER: Developments in PK/PD: optimizing efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J. Antimicrob. Agents 19: 291-298, 2002
5. CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-10, 1998
6. CRAIG, W. A.: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22: 89-96, 1995
7. MUELLER, M.; A. D. L. PENA & H. DERENDORF: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC Antimicrob. Agents Chemother. 48: 369-377, 2004
8. MOUTON, J. W. & A. A. VINKS: Pharmacokinetic/ pharmacodynamic modeling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics. Clin. Pharmacokinet. 44: 201-210, 2005
9. CZOCK, D. & F. KELLER: Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J. Pharmacokinet. Pharmacodyn. 34: 727-751, 2007
10. Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. M7-A7. Clinical and Laboratory Standards Institute, Wayne, Pa, 2006
11. Clinical and Laboratory Standards Institute: Methods for determining bactericidal activity of antimicrobial agents: approved guideline. M26-A. Clinical and Laboratory Standards Institute, Wayne, Pa, 1999
12. NIELSEN, E. I.; A. VIEBERG, E. LOWDIN, et al.: Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob. Agents Chemother. 51: 128-136, 2007
13. YANO, Y.; T. OGUMA, H. NAGATA, et al.: Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J. Pharm. Sci. 87: 1177-1183, 1998
14. AIKAWA, N.; S. KOHNO, M. KAKU, et al.: An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) - A clinical pharmacology study -. Jpn. J. Chemother. 56: 299-312, 2008
15. MEIJI Seika Kaisha, Ltd. Habekacin® Injection Package Insert Revised in April 2005 (7th edition)
16. FISMAN, D. N. & K. M. KAYE: Once-daily dosing of aminoglycoside antibiotics. Infect. Dis. Clin. North Am. 14: 475-487, 2000
17. PRINS, J. M. & P. SPEELMAN: Once-daily aminoglycosides: practical guidelines. Nether. J. Med. 52: 1-9, 1998
18. Shionogi & Co., Ltd. Vancomycin® for Injection 0.5 g Package Insert Revised in December 2006 (10th edition)
19. Astellas Pharma Inc. Targocid® for Injection 200 mg Package Insert Revised in December 2006 (13th edition)
20. SATO, N.; K. KIJIMA, T. KORESAWA, et al.: Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia. Drug Metab. Pharmacokinet. (in press)
21. Meiji Seika Kaisha, Ltd. Meiact® TABLETS100 Package Insert Revised in December 2005 (9th edition)
22. Daiichi Sankyo Company, Limited CRAVIT® Package Insert Revised in April 2007 (12th edition)
23. Maruho Co., Ltd. Farom® Tab. Package Insert Revised in April 2007 (12th edition)
24. BOSWELL, F. J.; J. P. ASHBY, J. M. ANDREWS, et al.: Effect of protein binding on the in vitro activity and pharmacodynamics of faropenem. J. Antimicrob. Chemother. 50: 525-532, 2002